Novel biomarkers for the detection of prostate cancer

Niels Asger Jakobsen¹, Freddie Charles Hamdy² and Richard John Bryant²

Abstract
Prostate-specific antigen (PSA) is widely used as a biomarker in the detection of prostate cancer and for decision making regarding treatment options, response to therapy, and clinical follow-up. Despite its widespread use, it is well recognised that PSA has suboptimal performance as a screening tool due to poor specificity, resulting in high negative biopsy rates and potential ‘over-diagnosis’ and ‘over-treatment’ of clinically insignificant cancers. In particular, PSA does not reliably distinguish either cancer from benign prostatic conditions, or ‘clinically significant’ from ‘indolent cancers’, and it is inaccurate in predicting disease burden and response to treatment. There is an urgent demand for novel biomarkers to address these clinical needs. This article provides an update on the novel candidate biomarkers in development, which have shown potential for improving the detection of clinically significant cases of this malignancy.

Keywords
Prostate cancer, biomarker, diagnosis, detection, screening, PSA, kallikrein panel

Introduction
Over 40,000 new prostate cancer cases are diagnosed annually in the United Kingdom (UK), and there are 10,000 prostate cancer-related deaths.¹ There are particular challenges to overcome regarding appropriate detection in individuals where treatment is warranted, whilst avoiding morbidity from unnecessary invasive investigations and treatment of ‘insignificant cancer’. ‘Over-diagnosis’ and ‘over-treatment’ of prostate cancer are well-recognised phenomena, and efforts are being made to minimise the numbers of men undergoing radical treatment if their tumour is unlikely to pose a threat. A particular challenge is to accurately predict the potential aggressiveness of newly diagnosed prostate cancer despite adjuncts such as the D’Amico Risk Classification.² Each of these areas of clinical need may benefit from novel prostate cancer biomarkers with performance characteristics surpassing those of prostate-specific antigen (PSA).

Principles of prostate cancer biomarkers
In cancer management, biomarkers may be used as indicators of the underlying disease state (Box 1).³ An ideal biomarker test should be safe, easy to perform, acceptable to the patient, inexpensive and reproducible. There are particular unmet clinical needs with regards to prostate cancer detection (Box 2) including distinction of malignant from benign causes of a raised PSA, distinction of ‘clinically significant’ early-stage disease from ‘insignificant’ indolent tumours, and the prediction of response to treatment. Novel
prostate cancer biomarkers need to provide improvements in these areas in order to prove clinically useful. This will be met only through rigorous pre-clinical studies and clinical evaluation prior to widespread use. A PubMed search of the term ‘prostate cancer biomarker’ reveals over 29,000 peer-reviewed publications, but to date few novel prostate cancer biomarkers are close to replacing PSA in regular clinical use. Numerous potential candidate biomarkers have been proposed (Table 1) including proteins and nucleic acids, and these can be detected with minimally invasive tests on urine or blood samples, or on tissue samples.

**Box 1. What is a biomarker?**

A biomarker is a ‘characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention’.3 Biochemical biomarkers may be detected in patient samples such as blood urine or tissue biopsies and are particularly useful in oncology if the marker is exclusively present or absent in malignant cells compared with normal cells, or if there is a significant difference in production, secretion, or accumulation compared with normal tissue. Prostate cancer-associated biomarkers may be useful for:

- Screening and/or diagnosis
- Clinical staging
- Estimating prognosis
- Predicting response to treatment
- Monitoring the response to treatment
- Detecting recurrence
- As potential therapeutic targets

**Box 2. Unmet needs to be addressed by novel prostate cancer biomarkers.**

1. Improved sensitivity and specificity: to facilitate more acceptable screening and distinguish prostate cancer from benign conditions.
2. Staging and prognosis: to distinguish clinically significant early-stage disease from non-aggressive indolent tumours.
3. Prediction of treatment response: to allow selection of optimal treatment options for patients, thereby reducing adverse effects in patients who may not elicit a response to therapy.

**PSA**

The discovery and purification of prostate-specific antigen (PSA) in 197575 revolutionised prostate cancer detection and management. PSA (human kallikrein 3, hK3, KLK-3) is a serine protease secreted by prostate epithelial cells into seminal fluid where it liquefies the ejaculate.76 PSA is normally present at low concentrations in blood but can be elevated by benign conditions and prostate cancer. Following United States (US) Food and Drug Administration (FDA) approval in 1986, PSA testing was used to monitor treatment response and identify disease relapse,78,79 and it has subsequently been used for prostate cancer detection, screening, staging and risk-stratification. In 1994 PSA was FDA approved for prostate cancer diagnosis, and this greatly increased testing in asymptomatic men with 35%–40% of men aged >65 years in the US undergoing testing by 1994.80 Half of men aged 65–79 now undergo PSA screening in the US,81–83 and a million prostate biopsies are performed annually.84

PSA testing has caused a stage-shift towards more newly diagnosed tumours being organ-confined, and PSA testing may be partly responsible for improving mortality rates. However, PSA-based screening can cause harms including ‘over-diagnosis’ and ‘over-treatment’ of ‘clinically insignificant’ tumours. As PSA is tissue-specific rather than cancer-specific, it has a poor specificity and positive predictive value particularly at ‘borderline’ PSA values of 3–10 ng/ml where the negative biopsy rate can be 60%–75%.4 It is difficult to determine an absolute PSA threshold to trigger a biopsy; a substantial proportion of men with a PSA below 4 ng/ml, for example, have prostate cancer, and there is no threshold below which there is no risk of cancer.5,6 Several PSA refinements have been investigated including free/total PSA ratio4 and PSA velocity.7–10

Whilst PSA testing can be used in screening programmes, the balance between benefits and adverse effects of PSA-based screening means further optimisation is necessary,11,12 and the numbers of men needed to screen and treat to save one life are currently unacceptably high.13 The Göteborg Screening Trial suggests that PSA-based screening may appear more beneficial with longer follow-up;14 however, in 2015 the UK National Screening Committee maintained its position to not recommend screening for prostate cancer.15 Recent evidence suggests PSA might be an early indicator of risk of developing lethal prostate cancer many years before diagnosis, and a single PSA test at age 44–49 can risk-stratify patients at greatest risk of future clinically significant disease and identify these men for subsequent screening.16 The PSA level at diagnosis is associated with tumour volume, stage and Gleason grade,17,78 therefore PSA combined with other factors can risk-stratify patients upon diagnosis.11,18,19 However, it is clear that there is a need for improved biomarkers above and beyond PSA.

**Novel protein biomarkers**

Most of the potentially novel prostate cancer biomarkers evaluated to date are proteins. Their quantification in blood samples involves relatively simple low-cost sample processing and well-established immunoassays such as enzyme-linked immunosorbent assay (ELISA). Well-performing protein biomarkers in blood samples are relatively uncommon, whilst biomarkers that necessitate evaluation in tissue samples are generally impractical for widespread pre-diagnostic use.
Additional kallikrein proteins

In addition to PSA, over a dozen other human kallikrein proteins have been identified, several of which have been evaluated as prostate cancer biomarkers. Of these, human kallikrein 2 (hK2) has reached the farthest stage of clinical development. hK2 is a serine protease which converts inactive pro-PSA to active PSA, and shares 80% of its primary structure with PSA. In contrast to PSA, hK2 is expressed more highly in malignant cells than benign epithelial cells, particularly in high-grade disease. Clinical studies suggest serum hK2 may help discriminate malignant from benign causes of a raised PSA.

Recently there has been interest in developing a combined panel of kallikreins for prostate cancer detection and screening. A panel of four kallikrein markers (total PSA, free PSA, intact PSA, and hK2) outperforms PSA testing in accurately detecting prostate cancer, and can potentially reduce the number of unnecessary false-negative biopsies undertaken in men with a raised PSA. For example an evaluation of the performance of the four kallikrein panel in the Prostate Testing for Cancer and Treatment (ProtecT) study in the UK demonstrated that use of this panel may potentially halve the number of unnecessary false-negative biopsies performed on men with an elevated PSA whilst missing only very few high-grade cancers. This could therefore reduce the adverse effects of over-detection of low-risk, low-volume tumours.

An additional novel approach to improve the performance of PSA-based screening is to combine the results of three blood tests (tPSA, fPSA and [-2]proPSA) using the mathematical formula \(([-2]\text{proPSA}/\text{fPSA}) \times \sqrt{\text{tPSA}}\) to calculate the ‘Prostate Health Index’ (phi). The phi result can improve the rate of prostate cancer detection compared with either tPSA or fPSA alone. Given the significant cost, invasiveness and potential adverse effects of undergoing a prostate biopsy, use of a multiple kallikrein panel may improve the cost-benefit ratio of a prostate cancer screening programme, and may replace PSA testing. Large-scale prospective evaluation of these panels of kallikrein markers is warranted.

RNA biomarkers

Abnormal gene expression is a hallmark of cancer, manifesting as either abnormal levels or mutated forms of gene transcription factors.
messenger ribonucleic acid (mRNA) or non-coding microRNAs (miRNA) and long non-coding RNA (lncRNA). RNA can be detected in serum, urine or tissue samples.\textsuperscript{95,96} Quantification of RNA biomarkers is more complex and costly than for proteins, and detection and quantification requires reverse-transcription polymerase chain reaction (RT-PCR), therefore RNA assays are not commonly used in clinical practice. RNA is unstable and degrades quickly in bodily fluids, therefore patient samples require rapid processing. Transcription-mediated amplification assays have recently been developed for some RNA biomarkers and have the advantage of simpler sample processing procedures and assay protocols, providing greater feasibility for use in the clinic.\textsuperscript{40,53}

**Prostate cancer antigen 3 (PCA3)**

PCA3 is a prostate-specific non-coding mRNA overexpressed by prostate cancer cells compared with benign prostate epithelium.\textsuperscript{41} PCA3 is readily detected in fresh voided urine samples following prostatic massage.\textsuperscript{42} A clinical-grade transcription-mediated amplification assay, ‘Progensa\textsuperscript{®} PCA3’, gained FDA approval in 2012 and can be used to aid decision making regarding repeat biopsy in men with a previous negative biopsy.\textsuperscript{40} While PCA3 has a better diagnostic performance than PSA,\textsuperscript{43–45} and its use may reduce the number of unnecessary biopsies,\textsuperscript{46,47} it does not add predictive value for Gleason score or tumour stage.\textsuperscript{48,49} In direct comparisons, the phi is a better predictor of significant prostate cancer at initial biopsy, and therefore more suitable for screening.\textsuperscript{50–52}

**Transmembrane protease serine 2 (TMPRSS2)-ERG fusion**

Approximately half of all prostate cancers contain a chromosomal rearrangement resulting in fusion of the TMPRSS2 gene with the v-ets erythroblastosis virus E26 oncogene (ERG).\textsuperscript{54} The resulting TMPRSS2-ERG gene fusion may play a role in the development of invasive prostate cancer.\textsuperscript{55} The TMPRSS2-ERG mRNA transcript is detectable in urine after prostatic massage with a reported specificity of >90% for prostate cancer.\textsuperscript{53,56,97} A pre-biopsy TMPRSS2-ERG ‘score’ incorporating urinary TMPRSS2-ERG mRNA and PSA mRNA measurement has been associated with tumour volume and Gleason grade at subsequent biopsy and prostatectomy.\textsuperscript{53,56} A recent prospective multicentre evaluation demonstrated that measurement of pre-biopsy urinary TMPRSS2-ERG adds additional predictive value to both the ERSPC risk calculator and PCA3 in both the diagnosis of prostate cancer and prediction of Gleason score and clinical stage.\textsuperscript{44}

**miRNA biomarkers**

miRNA are non-coding single-stranded RNA 18–25 nucleotides long which regulate gene expression. Numerous miRNA are over- or underexpressed in prostate cancer, and these miRNA expression profile changes may be associated with epithelial-to-mesenchymal transition, cellular migration and invasion, angiogenesis, and metastasis.\textsuperscript{57,58} As a result of their small size, miRNAs are resistant to endogenous ribonucleases, and can be detected by RT-PCR in plasma, serum and urine samples.\textsuperscript{80,82} miRNA profiling of serum samples may therefore be clinically useful in distinguishing aggressive from non-aggressive cancers.

Studies have shown that miRNA profiles can distinguish men with localised prostate cancer, men with metastatic disease, and control individuals.\textsuperscript{59–70} However, these studies have primarily involved relatively small numbers of patients, and to date no large prospective evaluation of miRNA performance has been reported. Moreover, there have been inconsistent results between published studies, and this may be due to technical difficulties in the extraction and quantitation of miRNA, along with a lack of standard clinical protocols for phlebotomy, sample processing, miRNA extraction and quantitation.\textsuperscript{71–74} Further work is therefore required before miRNA profiling may be used clinically but the promising results of these early studies suggest a potential role for miRNA profiling in future prostate cancer detection.

**Conclusions**

The fact that so many potentially novel prostate cancer biomarkers have been evaluated, yet none has to date replaced PSA testing to detect this malignancy, illustrates the difficulty in translating scientific discoveries from bench to bedside for routine clinical use. Encouraging progress has been made with several novel biomarkers that might fulfill important unmet clinical needs, but thorough evaluation, demonstrating superior performance compared with existing standards of care, is required prior to the widespread clinical use of a new biomarker. It is likely that the use of novel biomarkers as part of a risk calculator will yield optimal predictive value, as has been demonstrated by incorporating the four-kallikrein panel, fPSA and PCA3 into the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator (PCPTrc) and the European Randomised Study of Screening for Prostate Cancer (ERSPC) multivariable prediction model.\textsuperscript{97–99} Such an approach may reduce the over-diagnosis and over-treatment of prostate cancer whilst simultaneously enabling clinicians to focus on high-risk cases of localised prostate cancer in those men most likely to benefit from radical intervention.

**Conflicting interests**

The authors declare that there is no conflict of interest.
Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Ethical approval
Not applicable.

Informed consent
Not applicable.

Guarantor
RJB

Contributorship
NAJ and RJB researched the literature and conceived the article. NAJ wrote the first draft of the manuscript. NAJ, RJB and FCH reviewed and edited the manuscript, and all authors approved the final version.

Acknowledgements
None.

References
1. Cancer Research UK. Prostate cancer statistics, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer (2013, accessed 4 March 2016).
2. D’Amico AV, Moul J, Carroll PR, et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 2163–2172.
3. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95.
4. Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: Systematic review and meta-analysis. Eur Urol 2005; 48: 386–399.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239–2246.
6. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128–1133.
7. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215–2220.
8. D’Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125–135.
9. Ulmetr D, Serio AM, O’Brien MF, et al. Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008; 26: 835–841.
10. Vickers AJ and Brewster SF. PSA velocity and doubling time in diagnosis and prognosis of prostate cancer. Br J Med Surg Urol 2012; 5: 162–168.
11. Lilja H, Ulmetr D and Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268–278.
12. Payne H and Cornford P. Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol Semin Orig Invest 2011; 29: 593–601.
13. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981–990.
14. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725–732.
15. Louie KS. Screening for Prostate Cancer Review 2015 Update: Review against programme appraisal criteria for the UK National Screening Committee. Report, UK National Screening Committee, November 2015.
16. Vickers AJ, Ulmetr D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: Case-control study. BMJ 2013; 346: f2023.
17. Pinsky PF, Andriole G, Crawford ED, et al. Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 2007; 109: 1689–1695.
18. D’Amico A and Whittington R. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.
19. Makarov DV, Loeb S, Getzenberg RH, et al. Biomarkers for prostate cancer. Ann Rev Med 2009; 60: 139–151.
20. Darson MS, Pacelli A, Roche P, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker. Urology 1997; 49: 857–862.
21. Becker C, Pitroen T, Kiviniemi J, et al. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 2000; 46: 198–206.
22. Tremblay RR, Deperthes D, Têtu B, et al. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol 1997; 150: 455–459.
23. Darson MS, Pacelli A, Roche P, et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999; 53: 939–944.
24. Kwiatkowski MK, Recker F, Pitroen T, et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic ‘gray zone’ of total PSA 4 to 10 ng/mL. Urology 1998; 52: 360–365.
25. Nam RK, Diamandis EP, Toi A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 2000; 18: 1036–1036.
26. Becker C, Pitroen T, Pettersson K, et al. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men
with prostate-specific antigen levels 3.0 ng/mL or greater.

27. Martin BJ, Finlay JA, Sterling K, et al. Early detection of prostate cancer in African-American men through use of multiple biomarkers: Human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA). J Urol 2004; 171: 1439–1445.

28. Bryant RJ and Lilja HG. Emerging PSA-based tests to improve screening. Urol Clin North Am 2013; 41: 267–276.

29. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med 2008; 6: 19.

30. Vickers A, Cronin A, Roobol M, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication. J Clin Oncol 2010; 28: 2493–2498.

31. Benchikh A, Savage C, Cronin A, et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: An independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010; 10: 635.

32. Vickers AJ, Cronin AM, Roobol MJ, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010; 16: 3232–3239.

33. Vickers AJ, Cronin AM, Aus G, et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: Data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 2010; 116: 2612–2620.

34. Gupta A, Roobol MJ, Savage CJ, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: Data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands. Br J Cancer 2010; 103: 708–714.

35. Bryant RJ, Sjöberg DD, Vickers AJ, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT Study. J Natl Cancer Inst 2015; 107: djv095.

36. Morgan R, Boxall A, Bhatt A, et al. Engrailed-2 (EN2): A tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res 2011; 17: 1090–1098.

37. Pandha H, Sorensen KD, Orntoft TF, et al. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int 2012; 110: E287–E292.

38. Schostak M, Schwall GP, Poznanović S, et al. Annexin A3 in urine: A highly specific noninvasive marker for prostate cancer early detection. J Urol 2009; 181: 343–353.

39. Hamelin-Peyron C, Vlaeminck-Guilleb V, Haidous H, et al. Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability. Clin Biochem 2014; 47: 901–908.

40. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089–1095.

41. Hessels D and Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009; 6: 255–261.

42. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006; 8: 885–888.

43. Ferro M, Bruzzone D, Perdona S, et al. Prostate Health Index (PHI) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2–10 ng/mL. PLoS One 2013; 8: e67687.

44. Leyten GH, Hessels D, Jammink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014; 65: 534–542.

45. Chevli KK, Duff M, Walter P, et al. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. J Urol 2014; 191: 1743–1748.

46. Wei JT, Feng Z, Partin AW, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol 2014; 32: 4066–4072.

47. Merdan S, Tomlins SA, Barnett CL, et al. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer 2015; 121: 4071–4079.

48. Auprich M, Chun FK, Ward JF, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011; 59: 96–105.

49. Hessels D, van Gils MP, van Hooij O, et al. Predictive value of PCA3 in urinary sediments in determining clinicopathological characteristics of prostate cancer. Prostate 2010; 70: 10–16.

50. Seisen T, Rouprêt M, Brault D, et al. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate 2015; 75: 103–111.

51. Cantillo F, Russo GI, Ferro M, et al. Prognostic accuracy of Prostate Health Index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy. Urol Oncol 2015; 33: 163.e15–163.e23.

52. Cantillo F, Russo GI, Cicione A, et al. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol 2016; 34: 485–493.

53. Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3: 94ra72.

54. Tomlins SA, Bjartell A, Chimnaiyan AM, et al. ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol 2009; 56: 275–286.

55. Perner S, Mosquera JM, Demichelis F, et al. Fusion prostate cancer: An early molecular event associated with invasion. J Clin Oncol 2007; 25: 485–493.

56. Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3: 94ra72.

57. Tomlins SA, Bjartell A, Chimnaiyan AM, et al. ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol 2009; 56: 275–286.

58. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2:ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 882–888.

59. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007; 13: 5103–5108.

60. Catto JW, Alcaraz A, Bjartell A, et al. MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol 2011; 59: 671–681.
58. Gordanpour A, Nam RK, Sugar L, et al. MicroRNAs in prostate cancer: From biomarkers to molecularly-based therapeutics. *Prostate Cancer Prostatic Dis* 2012; 15: 314–319.

59. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc Natl Acad Sci* 2008; 105: 10513–10518.

60. Porkka KP, Pfeiffer MJ, Wallerting KK, et al. MicroRNA expression profiling in prostate cancer. *Cancer Res* 2007; 67: 6130–6135.

61. Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray. *PLoS One* 2009; 4: e6229.

62. Agaoğlu FY, Kovancilar M, Dizdar Y, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. *Tumor Biol* 2011; 32: 583–588.

63. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. *Prostate* 2011; 71: 326–331.

64. Moltzahn F, Olsen AB, Baechner L, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. *Cancer Res* 2011; 71: 550–560.

65. Mahn R, Heukamp LC, Rogenhofer S, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. *Urology* 2011; 77: 1265.e9–1265.e16.

66. Hao Y, Zhao Y, Zhao X, et al. Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. *Cancer Invest* 2011; 29: 318–324.

67. Chen ZH, Zhang GL, Li HR, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. *Prostate* 2012; 72: 1443–1452.

68. Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. *Br J Cancer* 2012; 106: 768–774.

69. Westermann AM, Schmidt D, Holdenrieder S, et al. Serum microRNAs as biomarkers in patients undergoing prostate biopsy: Results from a prospective multi-center study. *Anticancer Res* 2014; 34: 665–669.

70. Zhang X and Wu J. Prognostic role of microRNA-145 in prostate cancer: A systems review and meta-analysis. *Prostate Int* 2015; 3: 71–74.

71. Sita-Lumsden A, Dart DA, Waxman J, et al. Circulating microRNAs as potential new biomarkers for prostate cancer. *Br J Cancer* 2013; 108: 1925–1930.

72. Jackson BL, Grabowska A and Ratan HL. MicroRNA in prostate cancer: Functional importance and potential as circulating biomarkers. *BMC Cancer* 2014; 14: 930.

73. Ouyang H, Zhou Y, Zhang L, et al. Diagnostic value of microRNAs for urologic cancers: A systematic review and meta-analysis. *Medicine (Baltimore)* 2015; 94: e1272.

74. Fabris L, Ceder Y, Chinnaiyan AM, et al. The potential of microRNAs as prostate cancer biomarkers. *Eur Urol*. Epub ahead of print 21 January 2016. DOI: 10.1016/j.euro.2015.12.054.

75. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. *J Urol* 2002; 167: 960–964.

76. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. *J Clin Invest* 1985; 76: 1899–1903.

77. Sävblom C, Malm J, Giwercman A, et al. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. *The Prostate* 2005; 65: 66–72.

78. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. *N Engl J Med* 1987; 317: 909–916.

79. Ming Chu T and Murphy GP. What’s new in tumor markers for prostate cancer? *Urology* 1986; 27: 487–491.

80. Potosky AL, Feuer EJ and Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. *Epidemiol Rev* 2001; 23: 181–186.

81. Drazer MW, Hsu D, Schonberg MA, et al. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. *J Clin Oncol* 2011; 29: 1736–1743.

82. Sirovich BE, Schwartz LM and Woloshin S. Screening men for prostate and colorectal cancer in the United States: Does practice reflect the evidence? *JAMA* 2003; 289: 1414–1420.

83. Ross LE, Taylor YJ, Richardson LC, et al. Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002–2006. *J Natl Med Assoc* 2009; 101: 316–324.

84. Brawley OW. Prostate cancer epidemiology in the United States. *World J Urol* 2012; 30: 195–200.

85. Kumar A, Mikolajczyk SD, Goel AS, et al. Expression of pro form of prostate-specific antigen by malignant cells and its conversion to mature, active form by human kallikrein 2. *Cancer Res* 1997; 57: 3111–3114.

86. Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. *Crit Rev Clin Lab Sci* 1998; 35: 275–368.

87. Catalona WJ, Partin AW, Sandra MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. *J Urol* 2011; 185: 1650–1655.

88. Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting. *Eur Urol* 2011; 60: 214–222.

89. Houlgatte A, Vincendeau S, Desfemmes F, et al. Use of [-2]pro PSA and phi index for early detection of prostate cancer: A prospective study in a clinical setting. *Eur Urol* 2011; 60: 214–222.

90. Le BV, Griffin CR, Loeb S, et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. *J Urol* 2010; 183: 1355–1359.

91. Guazzoni G, Lazzeri M, Nava L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. *Eur Urol* 2012; 61: 455–466.
92. Filella X and Giménez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: A systematic review and meta-analysis. *Clin Chem Lab Med* 2013; 51: 729–739.

93. Jansen FH, van Schaik RH, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. *Eur Urol* 2010; 57: 921–927.

94. Isharwal S, Makarov DV, Sokoll LJ, et al. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. *Urology* 2011; 77: 763.e1–763.e6.

95. Wei JT. Urinary biomarkers for prostate cancer. *Curr Opin Urol* 2015; 25: 77–82.

96. Pickl JMA, Heckmann D, Ratz L, et al. Novel RNA markers in prostate cancer: Functional considerations and clinical translation. *Biomed Res Int* 2014; 2014: 765207.

97. Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. *Eur Urol*. Epub ahead of print 15 May 2015. DOI: 10.1016/j.eururo.2015.04.039.

98. Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. *Urology* 2014; 83: 1362–1367.

99. Vedder MM, de Bekker-Grob EW, Lilja HG, et al. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. *Eur Urol* 2014; 66: 1109–1115.